Data Management

Mainz Biomed partners with Quest Diagnostics for clinical trials lab services

Mainz Biomed, a provider of molecular genetic diagnostic solutions specializing in early detection of cancer, has partnered with Quest Diagnostics to provide clinical trials laboratory services related to colorectal screening tests.

Image: Adobe Stock (generated with AI)

December 24, 2024

Mainz Biomed, a provider of molecular genetic diagnostic solutions specializing in early detection of cancer, has partnered with Quest Diagnostics to provide clinical trials laboratory services related to colorectal screening tests, according to a press release.

The testing involves Mainz Biomed's stool-based ColoAlert test, which leverages PCR to detect cancer tumor DNA, to develop data for FDA validation.

Quest Diagnostics will offer laboratory support for ReconAAsense, a prospective clinical study with approximately 15,000 subjects from 150 U.S. sites.

As part of the deal, Mainz will offer Quest semi-exclusive testing service rights for 18 months related to the testing kit, dependent upon FDA approval.

"We are excited by the opportunity to work with Quest Diagnostics," Guido Baechler, CEO at Mainz Biomed, said in the release. "Quest is a leader in cancer diagnostics and knows how to scale these innovations to make them broadly accessible to patients in need. With their support, we are positioned to advance commercial development of our ColoAlert test in order to help more patients gain access to quality screening."